Diabetic neuropathy is one of the most common complications of diabetes. This compli-cation is peripheral neuropathy with predominant sensory impairment, and its symptoms begin with hyperesthesia and pain and gradually become hypoesthesia with the loss of nerve fibers. In some cases, lower limb amputation occurs when hypoalgesia makes it impossible to be aware of trauma or mechanical stimuli. On the other hand, up to 50% of these complications are asympto-matic and tend to delay early detection. Therefore, sensitive and reliable biomarkers for diabetic neuropathy are needed for an early diagnosis of this condition. This review focuses on systemic biomarkers that may be useful at this time. It also describes research on the relationship between target gene polymorphisms and pathological conditions. Finally, we also introduce current information on regenerative therapy, which is expected to be a therapeutic approach when the pathological condition has progressed and nerve degeneration has been completed.
CITATION STYLE
Fujita, Y., Murakami, T., & Nakamura, A. (2021, March 1). Recent advances in biomarkers and regenerative medicine for diabetic neuropathy. International Journal of Molecular Sciences. MDPI AG. https://doi.org/10.3390/ijms22052301
Mendeley helps you to discover research relevant for your work.